Efficacy and safety of human umbilical cord-derived mesenchymal stem cells versus placebo added to second-line therapy in patients with steroid-refractory acute graft-versus-host disease: a multicentre, randomized, double-blind, phase 2 trial
Erlie Jiang, Kun Qian, Lu Wang, Donglin Yang, Yangliu Shao, Liangding Hu, Yuhang Li, Chen Yao, Mingzhe Han, Xiaoqiang Hou, Daihong Liu · 2024
Read Efficacy and safety of human umbilical cord-derived mesenchymal stem cells versus placebo added to second-line therapy in patients with steroid-refractory acute graft-versus-host disease: a multicentre, randomized, double-blind, phase 2 trial by Erlie Jiang, Kun Qian, Lu Wang, Donglin Yang, Yangliu Shao, Liangding Hu, Yuhang Li, Chen Yao, Mingzhe Han, Xiaoqiang Hou, Daihong Liu (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11590523.txt.
Description
A team led by Erlie Jiang ran a phase two trial of cord-blood stem cells for a severe reaction after bone marrow transplant, where donor cells attack the patient. Steroid drugs fail many of these patients, and stem cells are a hopeful second line that lacked firm trials. Seventy-eight patients at seven centers got stem cells or a dummy infusion, each with standard second drugs.
By day twenty-eight, sixty percent of the stem cell group had responded, against half of the control group, a gap too small to prove. Later chronic disease rates leaned lower with stem cells. Response came at a median of two weeks. The authors call for larger trials.
Catalog record
| CREATOR | Erlie Jiang, Kun Qian, Lu Wang, Donglin Yang, Yangliu Shao, Liangding Hu, Yuhang Li, Chen Yao, Mingzhe Han, Xiaoqiang Hou, Daihong Liu |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 51 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |